A NOVEL TREATMENT FOR TYPE B INSULIN RESISTANCE

Case Presentation: A 20-year-old African-American woman with a history of presumed DM type 2 with total daily dose (TDD) of 16 units of insulin (0.27 units/kg), mixed connective tissue disease and hypothyroidism, who presented with seizure-like activity and acute kidney injury due to lupus nephritis...

Full description

Saved in:
Bibliographic Details
Published inEndocrine practice Vol. 23; p. 304
Main Authors Esquivel, Mary Angelynne, Ricciuto, Jessica, McFarland, Meredith, Gigliotti, Benjamin, Miragaya, Joanna, Correa, Ricardo
Format Journal Article
LanguageEnglish
Published Jacksonville Elsevier Limited 01.04.2017
Subjects
Glucose
Hyperglycemia
Insulin resistance
Online AccessGet full text

Cover

More Information
Summary:Case Presentation: A 20-year-old African-American woman with a history of presumed DM type 2 with total daily dose (TDD) of 16 units of insulin (0.27 units/kg), mixed connective tissue disease and hypothyroidism, who presented with seizure-like activity and acute kidney injury due to lupus nephritis. In this case report we describe the use of empagliflozin, an SGLT2 inhibitor, as a novel therapy for Type B insulin resistance, that ultimately led to remarkable BG improvement and...
ISSN:1530-891X
1934-2403